Microbial Natural Products

Natural Products in Chemical Biology

Volumn , Issue , 2012, Pages 65-108

  Sanchez, Sergio ^a   Guzmán Trampe, Silvia ^a   Ávalos, Mariana ^a   Ruiz, Beatriz ^a   Rodríguez Sanoja, Romina ^a   Jiménez Estrada, Manuel ^b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Antibacterials, antifungals, enzyme inhibitors, antitumor, and structural complexity; Biologically active portions, unusual chemical structures in therapeutics; Microbial chemical diversity, in drug discovery and pharmaceuticals; Microbial natural products' chemical diversity, and metagenomics; Product structural diversity, novel lead compounds in therapeutics

Indexed keywords

EID: 84886136455     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118391815.ch3     Document Type: Chapter

References (88)

1. Demain AL, Sánchez S. Microbial drug discovery. J. Antibiot. 2009;62:5-16
2. Handelsman J, Rondon MR, Brady S, Clardy J, Goodman RM. Molecular biological provides access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. 1998;5:R245-R249.
3. Pearce C. Biologically active fungal metabolites. Adv. Appl. Microbiol. 1997;44: 1-80.
4. Pedros-Alio C. Marine microbial diversity: can it be determined? Trends Microbiol. 2006;14:257-263.
5. Hawksworth DL. The fungal dimension of biodiversity, magnitude, significance and conservation. Mycol. Res. 1991;95:641-655
6. Davies J. Millennium bugs. Trends Biochem. Sci. 1999;24:M2-M5.
7. Priscu JC, Fritsen CH, Adams EE, Giovannoni SJ, Paerl HW, McKay CP, Doran PT, Gordon DA, Lanoil BD, Pinckney JL. Perennial Antarctic lake ice: an oasis for life in a polar desert. Scienc. 1998;280:2095-2098.
8. Berdy J. Bioactive microbial metabolites a personal review. J. Antibiot. (Tokyo) 2005; 58:1-26.
9. Stork CM. Antibiotics, antifungals, and antivirals. In: Goldfrank's Toxicologic Emergencies. Nelson LH, Flomenbaum N, Goldfrank LR, Hoffman RL, Howland MD, Lewin NA, eds. 2006. McGraw-Hill, New York.
10. Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin. Infec. Dis. 1997;24:S266-S275.
11. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. 1999;74: 613-634.
12. Stephan H, Kempter C, Metzger JW, Jung G, Potterat O, Pfefferle C, Fiedler HP. Kanchanamycins, new polyol macrolide antibiotics produced by Streptomyces olivaceus Tii 4018 II. Structure elucidation. J. Antibiot. 1996;49:765-769.
13. Wehrli W. Ansamycins. chemistry, biosynthesis and biological activity. Top. Curr. Chem. 1977;72:21-49.
14. Mukhtar TA, Wright GD. Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem. Rev. 2005;105:529-542.
15. Dutton JC, Haxwell M, McArthur H, Wax RG. Peptide Antibiotics: Discovery, Modes of Action, and Applications. 2002. Marcel Dekker, New York.
16. Georgopapadakou NH. Antifungals targeted to cell wall: focus on β-1,3-glucan synthase. Expert Opin. Investig. Drug. 2001;10:269-280.
17. Van Lanen S, Ben S. Microbial genomics for the improvement of natural product discovery. Curr. Opin. Microbiol. 2006;9:252-260.
18. Cragg GM, Kingston DGI, Newman DJ. Anticancer Agents from Natural Products. 2005 CRC Press. Boca Raton, FL.
19. Qu X, Ren J, Riccelli P, Benight A, Chaires J. Enthalpy/Entropy compensation: influence of DNA flanking sequence on the binding of 7-amino actinomycin D to its primary binding site in short DNA duplexes. Biochemistr. 2003;42:11960-11967.
20. Strobel G, Bryn D. Bioprospecting for microbial endophytes and their natural products. Microbiol. Mol. Biol. Rev. 2003;67:491-502.
21. Park G, Tomlinson J, Misenheimer J, Kucera G, Manderville R. Photo-induced cytotoxicity of prodigiosin analogues. Bull. Korean Chem. Soc. 2007;28:49-52.
22. Tooth JA, Davis MW, Avery LA. avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 1997;16:5867-5879.
23. Mishima H, Ide J, Muramatsu S, Ono M. Milbemycins, a new family of macrolide antibiotics. Structure determination of milbemycins D, E, F, G, H, J and K. J. Antibiot. 1983;36:980-990.
24. Westley JW. Polyether antibiotics: versatile carboxylic acid ionophores produced by Streptomyces. Adv. Appl. Microbiol. 1977;22:177-223.
25. Matabudul DK, Lumley ID, Points JS. The determination of 5 anticoccidial drugs (nicarbazin, lasalocid, monensin, salinomycin and narasin) in animal livers and eggs by liquid chromatography linked with tandem mass spectrometry (LC-MS-MS). Analys. 2002;127:760-768.
26. Umezawa H. Low-molecular-weight enzyme inhibitors of microbial origin. Ann. Rev. Microbiol. 1982;36:75-99.
27. Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. J. Antibiot. 1987;40: 1081-1085.
28. Liu DZ, Wang F, Liao TG, Tang JG, Steglich W, Zhu HJ, Liu JK. Vibralactone: a lipase inhibitor with an unusual fused beta-lactone of the basidiomycete Boreostereum vibrans. Org. Lett. 2006;8:5749-5752.
29. Ondetti MA, Rubin B, Cushman DW. Enzyme of the rennin-angiotensin system and their inhibitors. Annu. Rev. Biochem. 1982;51:283-308.
30. Rhee KH. Purification and identification of an antifungal agent from Streptomyces sp. KH-614 antagonistic to rice blast fungus, Pyricularia oryzae. J. Microbiol. Biotechnol. 2003;13:984-988.
31. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. 2002;9:195-217.
32. Izumida H, Miki W, Sano H, Endo M. Agar plate method, a new assay for chitinase inhibitors using a chitin-degrading bacterium. J. Marine Biotechnol. 1995;2:163-166.
33. Song YC, Li H, Ye YH, Shan CY, Yang YM, Tan RX. Endophytic naphthopyrone metabolites are co-inhibitors of xanthine oxidase, SW1116 cell and some microbial growths. FEMS Microbiol. Lett. 2004;241:67-72.
34. Paterson RRM. Fungal enzyme inhibitors as pharmaceuticals, toxins and scourge of PCR. Curr. Enzyme Inhib. 2008;4:46-59.
35. Duke SO, Cantrell CL, Meepagal KM, Wedge DE, Tabanca N, Schrader KK. Natural toxins for use in pest management. Toxin. 2010;2:1943-1962.
36. Strobel G, Sugawara F, Hershenhorn J. Pathogens and their products affecting weedy plants. Phytoparasitic. 1992;20:307-323.
37. Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials. Arch. Dis. Child. 2010;95:673-680.
38. Barrios-González J, Miranda RU. Biotechnological production and applications of statins. Appl. Microbiol. Biotechnol. 2010;85:869-883.
39. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992;33:1569-1582.
40. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteent K, Liesch J, Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. U.S.A. 1980;77:3957-3961.
41. Subazini TK, Kumar GR. Characterization of lovastatin biosynthetic cluster proteins in Aspergillus terreus strain ATCC 20542. Bioinformatio. 2011;6:250-254.
42. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmacol. Ther. 2011;130:177-190.
43. Bakhireva LN, Shainline MR, Carter S, Robinson S, Beaton SJ, Nawarskas JJ, Gunter MJ. Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. Pharmacotherap. 2010;30:879-887.
44. Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol. Res. 2011;63:172-180.
45. Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist 2011;17: 244-255.
46. Tang TT, Song Y, Ding YJ, Liao YH, Yu X, Du R, Xiao H, Yuan J, Zhou ZH, Liao MY, Yao R, Jevallee H, Shi GP, Cheng X. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J. Lipid Res. 2011;52:1023-1032.
47. Casirola DM, Ferraris RP. Alpha-glucosidase inhibitors prevent diet induced increases in intestinal sugar transport in diabetic mice. Metabolis. 2006;55:832-841.
48. Van de Laar F. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc. Health Risk Manag. 2008;4:1189-1195.
49. Geng P, Qiu F, Zhu Y, Bai G. Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of a-amylase. Carbohydr. Res. 2008;343:882-892.
50. Deppenmeier U, Hoffmeister M, Prust C. Biochemistry and biotechnological applications of Gluconobacter strains. Appl. Microbiol. Biotechnol. 2002;60:233-242.
51. Camerino M, Thompson P, Chalmer D. New drugs for diabetes: the design and molecular modelling of a-amylase peptidomimetics. Proc. 4th Int. Peptide Symp. Australian Peptide Association, Australia, 2007. pp. 1-2.
52. Heyl DL, Fernandes S, Khullar L, Stephens J, Blaney E, Opang-Owusu H, Stahelin B, Pasko T, Jacobs J, Bailey D, Brown D, Milletti MC. Correlation of LUMO localization with the alpha-amylase inhibition constant in a tendamistat-based series of linear and cyclic peptides. Bioorg. Med. Chem. 2005;13:4262-4268.
53. Heyl DL, Tobwala S, Lucas LS, Nandanie AD, Himm RW, Kappler J, Blaney EJ, Groom J, Asbill J, Nzoma JK, Jarosz C, Palamma H, Schullery SE. Peptide inhibitors of a-amylase based on tendamistat: development of analogues with φ-amino acids linking critical binding segments. Prot. Pept. Lett. 2005;12:275-280.
54. Rehm S, Han S, Hassani I, Sokocevic A, Jonker HRA, Engels JW, Schwalbe H. The high resolution NMR structure of parvulustat (Z-2685) from Streptomyces parvulus FH-1641: comparison with tendamistat from Streptomyces tendae 4158. Chem. Biol. Chem. 2009;10:119-127.
55. Souren P, Hou CT, Kang SC. a-Glucosidase inhibitory activities of 10-hydroxy-8(E)- octadecenoic acid: an intermediate of bioconversion of oleic acid to 7,10-dihydroxy- 8(E)-octadecenoic acid. New Biotechnol. 2010;27:419-423.
56. Wu M, Singh SB, Wang J, Chung CC, Salituro S, Karanam VB, Lee SH, Powles M, Ellsworth KP, Lassman ME, Miller C, Myers RW, Tota MR, Zhang BB, Li C. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. U.S.A. 2011;108:5378-5383.
57. Kahan BD. Forty years of publication of transplantation proceedings-the second decade: the cyclosporine revolution. Transplant Proc. 2009;41:1423-1437.
58. Bentley R. Mycophenolic acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem. Rev. 2000;100:3801-3825.
59. Sneader W. Drug Discovery: A History. 2005. John Wiley and Sons, Ltd., England.
60. Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 2011;74: 900-907.
61. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochia T. FK-506, a novel immunosuppressant isolated from a Streptomyces. J. Antibiot. 1987;60:1256-1265.
62. Cheng X-C, Kihara T, Ying X, Uramoto M, Osada H, Kusakabe H, Wang B-N, Kobayashi Y, Ko K, Yamaguchi I, Shen Y-C, Isono K. A new antibiotic, tautomycetin. J. Antibiot. 1989;42:141-144.
63. Shim J-H, Lee H-K, Chang E-J, Chae W-J, Han J-H, Han D-J, Morio T, Yang JJ, Bothwell A, Lee S-K. Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc. Natl. Acad. Sci. U.S.A. 2002;99: 10617-10622.
64. Han DJ, Jeong YL, Wee YM, Lee AY, Lee HK, Ha JC, Lee SK, Kim SC. Tautomycetin as a novel immunosuppressant in transplantation. Transplant Proc. 2003; 35:547.
65. Snyder S, Sherwood T, Ross A. Total syntheses of Dalesconol A and B. Angew. Chem. Int. Ed. 2010;49:5146-5150.
66. Kim D, Lee JS, Park YK, Kim JF, Jeong H, Oh TK, Kim BS, Lee CH. Biosynthesis of antibiotic prodiginines in the marine bacterium Hahella chejuensis KCTC 2396. J. Appl. Microbiol. 2007;102:937-944.
67. Williamson NR, Fineran PC, Leeper FJ, Salmond GPC. The biosynthesis and regulation of bacterial prodiginines. Nat. Rev. Microbiol. 2006;4:887-899.
68. Lee JS, Kim YS, Park S, Kim J, Kang SJ, Lee MH, Ryu S, Choi JM, Oh TK, Yoon JH. Exceptional production of both prodigiosin and cycloprodigiosin as major metabolic constituents by a novel marine bacterium, Zooshikella rubidus S1-1. Appl. Environ. Microbiol. 2001;77:4967-4973.
69. Liu R, Cui CB, Duan L, Gu QQ, Zhu VW. Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a spong-derived actinomycete Saccharopolyspora sp. nov. Arch. Pharm. Res. 2005;28:1341-1344.
70. Luti KJ, Matuvina F. Streptomyces coelicolor increases the production of undecylprodigiosin when interacted with Bacillus subtilis. Biotechnol. Lett. 2011;33: 113-118.
71. Kawauchi K, Shibutani K, Yagisawa H, Kamata H, Nakatsuji S, Anzai H, Yokoyama Y, Ikegami Y, Moriyama Y, Hirata H. A possible immunosuppressant, cycloprodigiosin hydrochloride, obtained from Pseudoalteromonas denitrificans. Biochem. Biophys. Res. Commun. 1997;237:543-547.
72. Nakajyo S, Shimizu K, Kametani A. On the inhibitory mechanism of bassianolide a cyclodepsipeptide, in acetylcholine-induced contraction in guinea-pig taenia coli. Jpn. J. Pharmacol. 1983;33:573-582.
73. Xu Y, Orozco R, Wijeratne EMK, Espinosa-Artiles P, Gunatilaka AAL, Stock P, Molnár l. Biosynthesis of the cyclooligomer depsipeptide beauvericin, a virulence factor of the entomopathogenic fungus Beauveria bassiana. Chem. Biol. 2008;15:898-907.
74. Butt TM, Ben El Hadj N, Skrobek A, Ravensberg WJ, Wang C, Lange CM, Vey A, Shah UK, Dudley E. Mass spectrometry as a tool for the selective profiling of destruxins; their first identification in Lecanicillium longisporum. Rapid Commun. Mass Spectrom. 2009;23:1426-1434.
75. Waldron C, Matsushima P, Rosteck PR, Broughton MC, Turner J, Madduri K. Cloning and analysis of the spinosad biosynthetic gene cluster of Saccharopolyspora spinosa. Chem. Biol. 2001;8:487-499.
76. Kirst HA. The spinosyn family of insecticides: realizing the potential of natural products research. J. Antibiot. 2010;63:101-111.
77. Hahn DR, Gustafson G, Waldron C, Bullard B, Jackson JD, Mitchell J. Butenyl spinosyns, a natural example of genetic engineering of antibiotic biosynthetic genes. J. Ind. Microbiol. Biotechnol. 2006;33:94-104.
78. Kim J-R, Yeon S-H, Kim H-S, Ahn Y-J. Larvicidal activity against Plutella xylostella of cordycepin from the fruiting body of Cordyceps militaris. Pest Manag. Sci. 2002;58:713-717.
79. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol. 2006;55:809-818.
80. Eschenauer G, DePestel DD, Carver PL. Comparison of echinocandin antifungals. Ther. Clin. Risk Manag. 2007;3:71-97.
81. Firn RD, Jones CG. Natural products-a simple model to explain chemical diversity. Nat. Prod. Rep. 2003;20:382-391.
82. Harvey AL. Natural products in drug discovery. Drug Discov. Today 2008;13:894-901.
83. Hübel K, Leßmann T, Waldmann H. Chemical biology-identification of small molecule modulators of cellular activity by natural product inspired synthesis. Chem. Soc. Rev. 2008;37:1361-1374.
84. Klekota J, Roth FP. Chemical substructures that enrich for biological activity. Bioinformation 2008;24:2518-2525.
85. Osada H, Hertweck C. Exploring the chemical space of microbial natural products. Curr. Opin. Chem. Biol. 2009;13:133-134.
86. Schmidt EW. The hidden diversity of ribosomal peptide natural products. BMC Biol. 2010;8:83.
87. Schuffenhauer A, Brown N. Chemical diversity and biological activity. Drug Discov. Today Technol. 2006;3:387-395.
88. Sing SB, Pelaez F. Biodiversity, chemical diversity and drug discovery. Prog. Drug Res. 2008;65:142-174.